Get Updates


FORCE advocates for families facing hereditary breast and ovarian cancer in areas such as access to care, research funding, insurance, and privacy.

| More


FORCE joined The Ad Hoc Group for Medical Research, representing over 300 organizations, in recommending a $2 billion FY18 increase for NIH, in addition to funds included in the 21st Century Cures Act for targeted initiatives.

Advocate Melanie Nix shares why she is passionate about health policy efforts. Read her blog...

FORCE VP of Advocacy is in NY today participating in the Basser Center for BRCA's "The Intersection of Cancer Genetics, Law and Advocacy" event.

FORCE joined Harvard, several patient advocacy orgs and pharma companies to submit FDA comments regarding the voluntary provision of plain language summaries of aggregate results to research subjects.

FORCE is on Capitol Hill today...part of a CIBR Medical Technology Showcase team presenting on new cancer imaging technology & fighting for research funding.

Today FORCE met with Senate HELP committee staff to discuss concerns about H.R. 1313. Read more...

FORCE participated in NCI's “Approaches to Blue Ribbon Panel Recommendations: The Case of Lynch Syndrome" Workshop.
More details...


Take Action

Read our statement in response to the FDA decision, and our testimony presented at the FDA hearing on Avastin.

If you are a woman living with advanced hereditary breast cancer please take our metastatic breast cancer survey and help us advocate for more options for treating hereditary breast cancer.

The cancer drug Avastin has been studied as a treatment for advanced breast and ovarian cancer. Not all women with advanced cancer respond equally to the medication. The FDA has decided that the benefits of Avastin do not outweigh the risks for women with advanced breast cancer and the agency has removed Avastin from the list of approved breast cancer therapies. While FORCE respects the FDA's decision, we are disappointed with this outcome. There are women with advanced breast cancer for whom Avastin appears to work well. FORCE has prepared a statement in response to the FDA recent ruling.

FORCE's concerns

  • FORCE is concerned that this label change will restrict access to the medication for women who are currently on and benefiting from the drug.
  • We are concerned that this change will restrict access for women who are newly diagnosed with metastatic breast and ovarian cancer who might benefit from the medication but will not be presented with it as a treatment option.
  • Further, we are concerned that insurance companies may use the FDA decision to restrict reimbursement even for those women who are currently on and responding to the medication.

More research needed

More research is needed to better determine which portion of breast cancer patients most benefit from Avastin. The decision of whether or not a woman with stage IV breast cancer should have access to Avastin should be made after discussion and consideration of benefits vs. risks with her health care team.

FORCE:Facing Our Risk of Cancer Empowered